Related Experiment Video
Updated: May 28, 2026

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
Published on: December 23, 2016
A sulfonated diblock copolymer exhibits reversible antiplatelet activity and enables aqueous dipyridamole formulation
Aleksandra Frackiewicz1, Karol Depczynski1, Magdalena Obłoza2
1Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2C St., 15-089 Bialystok, Poland. aleksandra.frackiewicz@umb.edu.pl.
Abstract:
Sulfonated block copolymers modulate biological function via charge-charge interactions. We report a sulfonated diblock copolymer - poly(sodium styrene sulfonate)-poly(sodium acrylamido undecanoate) (PSSNa38-b-PAaU10) with intrinsic charge-mediated platelet inhibition, and externally triggered reversibility, which also stabilizes poorly water-soluble dipyridamole in aqueous media. The amphiphilic architecture facilitated complete encapsulation at 5 wt% loading through block segregation and hydrophobic domain formation. Screening identified PSSNa38-b-PAaU10 as the most potent inhibitor of platelet aggregation in vitro. The antiplatelet activity of polymer-dipyridamole complex was mediated by the sulfonated block rather than the small molecule. Inhibition persisted under static and flow conditions, confirmed by scanning electron microscopy and lactate dehydrogenase release assay, without evidence of acute cytotoxicity. Polymer-mediated effects were attenuated via polyelectrolyte complexation with a cationic heparin-binding copolymer, enabling reversible regulation of platelet function without directly neutralizing dipyridamole. Ex vivo analyses performed after intravenous administration confirmed antiplatelet efficacy. These findings establish PSSNa38-b-PAaU10 as a diblock copolymer with intrinsic and reversibly controlled antiplatelet activity that also supports aqueous dipyridamole formulation, providing a basis for responsive antithrombotic systems.
More Related Videos
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Oral Drug Delivery Systems: Delayed-Release Systems
Modified-Release Drug Delivery Systems: Rate-Programmed II
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Bioavailability Enhancement: Drug Permeability Enhancement

